nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftibuten—Cefdinir—MPO—urinary bladder cancer	0.00367	1	CrCbGaD
Ceftibuten—Eructation—Epirubicin—urinary bladder cancer	0.00356	0.00363	CcSEcCtD
Ceftibuten—Renal failure—Etoposide—urinary bladder cancer	0.00355	0.00362	CcSEcCtD
Ceftibuten—Melaena—Epirubicin—urinary bladder cancer	0.00354	0.00361	CcSEcCtD
Ceftibuten—Jaundice—Etoposide—urinary bladder cancer	0.00352	0.00359	CcSEcCtD
Ceftibuten—Candida infection—Epirubicin—urinary bladder cancer	0.00346	0.00353	CcSEcCtD
Ceftibuten—Vaginal infection—Epirubicin—urinary bladder cancer	0.00342	0.00349	CcSEcCtD
Ceftibuten—Chills—Gemcitabine—urinary bladder cancer	0.00341	0.00348	CcSEcCtD
Ceftibuten—Convulsion—Thiotepa—urinary bladder cancer	0.00341	0.00347	CcSEcCtD
Ceftibuten—Aplastic anaemia—Epirubicin—urinary bladder cancer	0.0034	0.00347	CcSEcCtD
Ceftibuten—Agranulocytosis—Etoposide—urinary bladder cancer	0.00337	0.00344	CcSEcCtD
Ceftibuten—Vaginal inflammation—Doxorubicin—urinary bladder cancer	0.00335	0.00342	CcSEcCtD
Ceftibuten—Eructation—Doxorubicin—urinary bladder cancer	0.00329	0.00336	CcSEcCtD
Ceftibuten—Melaena—Doxorubicin—urinary bladder cancer	0.00327	0.00334	CcSEcCtD
Ceftibuten—Candida infection—Doxorubicin—urinary bladder cancer	0.0032	0.00326	CcSEcCtD
Ceftibuten—Vaginal infection—Doxorubicin—urinary bladder cancer	0.00317	0.00323	CcSEcCtD
Ceftibuten—Aplastic anaemia—Doxorubicin—urinary bladder cancer	0.00315	0.00321	CcSEcCtD
Ceftibuten—Erythema multiforme—Etoposide—urinary bladder cancer	0.00307	0.00313	CcSEcCtD
Ceftibuten—Anorexia—Thiotepa—urinary bladder cancer	0.00306	0.00312	CcSEcCtD
Ceftibuten—Flatulence—Cisplatin—urinary bladder cancer	0.00304	0.0031	CcSEcCtD
Ceftibuten—Chills—Etoposide—urinary bladder cancer	0.00291	0.00297	CcSEcCtD
Ceftibuten—Paraesthesia—Thiotepa—urinary bladder cancer	0.00288	0.00294	CcSEcCtD
Ceftibuten—Somnolence—Thiotepa—urinary bladder cancer	0.00285	0.00291	CcSEcCtD
Ceftibuten—Dyspepsia—Thiotepa—urinary bladder cancer	0.00283	0.00288	CcSEcCtD
Ceftibuten—Convulsion—Fluorouracil—urinary bladder cancer	0.00282	0.00287	CcSEcCtD
Ceftibuten—Decreased appetite—Thiotepa—urinary bladder cancer	0.00279	0.00285	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00277	0.00283	CcSEcCtD
Ceftibuten—Fatigue—Thiotepa—urinary bladder cancer	0.00277	0.00282	CcSEcCtD
Ceftibuten—Dysgeusia—Etoposide—urinary bladder cancer	0.00277	0.00282	CcSEcCtD
Ceftibuten—Renal impairment—Epirubicin—urinary bladder cancer	0.00276	0.00282	CcSEcCtD
Ceftibuten—Constipation—Thiotepa—urinary bladder cancer	0.00275	0.0028	CcSEcCtD
Ceftibuten—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.0027	0.00275	CcSEcCtD
Ceftibuten—Irritability—Methotrexate—urinary bladder cancer	0.00268	0.00273	CcSEcCtD
Ceftibuten—Convulsion—Cisplatin—urinary bladder cancer	0.00267	0.00272	CcSEcCtD
Ceftibuten—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00266	0.00271	CcSEcCtD
Ceftibuten—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00263	0.00268	CcSEcCtD
Ceftibuten—Anorexia—Gemcitabine—urinary bladder cancer	0.00257	0.00262	CcSEcCtD
Ceftibuten—Renal impairment—Doxorubicin—urinary bladder cancer	0.00256	0.00261	CcSEcCtD
Ceftibuten—Urticaria—Thiotepa—urinary bladder cancer	0.00255	0.0026	CcSEcCtD
Ceftibuten—Body temperature increased—Thiotepa—urinary bladder cancer	0.00254	0.00259	CcSEcCtD
Ceftibuten—Abdominal pain—Thiotepa—urinary bladder cancer	0.00254	0.00259	CcSEcCtD
Ceftibuten—Anorexia—Fluorouracil—urinary bladder cancer	0.00253	0.00258	CcSEcCtD
Ceftibuten—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.00253	0.00258	CcSEcCtD
Ceftibuten—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00252	0.00257	CcSEcCtD
Ceftibuten—Convulsion—Etoposide—urinary bladder cancer	0.00245	0.0025	CcSEcCtD
Ceftibuten—Dehydration—Epirubicin—urinary bladder cancer	0.00245	0.00249	CcSEcCtD
Ceftibuten—Insomnia—Gemcitabine—urinary bladder cancer	0.00244	0.00249	CcSEcCtD
Ceftibuten—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00243	0.00247	CcSEcCtD
Ceftibuten—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00241	0.00245	CcSEcCtD
Ceftibuten—Insomnia—Fluorouracil—urinary bladder cancer	0.0024	0.00245	CcSEcCtD
Ceftibuten—Somnolence—Gemcitabine—urinary bladder cancer	0.0024	0.00245	CcSEcCtD
Ceftibuten—Anorexia—Cisplatin—urinary bladder cancer	0.0024	0.00245	CcSEcCtD
Ceftibuten—SLC15A1—epithelium—urinary bladder cancer	0.00239	0.154	CbGeAlD
Ceftibuten—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00238	0.00243	CcSEcCtD
Ceftibuten—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.00237	0.00241	CcSEcCtD
Ceftibuten—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00237	0.00241	CcSEcCtD
Ceftibuten—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00237	0.00241	CcSEcCtD
Ceftibuten—Somnolence—Fluorouracil—urinary bladder cancer	0.00236	0.00241	CcSEcCtD
Ceftibuten—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00235	0.00239	CcSEcCtD
Ceftibuten—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00234	0.00238	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00233	0.00238	CcSEcCtD
Ceftibuten—Fatigue—Gemcitabine—urinary bladder cancer	0.00233	0.00237	CcSEcCtD
Ceftibuten—Constipation—Gemcitabine—urinary bladder cancer	0.00231	0.00235	CcSEcCtD
Ceftibuten—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00231	0.00235	CcSEcCtD
Ceftibuten—Pancytopenia—Methotrexate—urinary bladder cancer	0.00231	0.00235	CcSEcCtD
Ceftibuten—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00231	0.00235	CcSEcCtD
Ceftibuten—Asthenia—Thiotepa—urinary bladder cancer	0.0023	0.00235	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00229	0.00234	CcSEcCtD
Ceftibuten—Dysuria—Methotrexate—urinary bladder cancer	0.00227	0.00232	CcSEcCtD
Ceftibuten—Neutropenia—Methotrexate—urinary bladder cancer	0.00227	0.00232	CcSEcCtD
Ceftibuten—Pruritus—Thiotepa—urinary bladder cancer	0.00227	0.00232	CcSEcCtD
Ceftibuten—Dehydration—Doxorubicin—urinary bladder cancer	0.00226	0.00231	CcSEcCtD
Ceftibuten—Paraesthesia—Cisplatin—urinary bladder cancer	0.00226	0.0023	CcSEcCtD
Ceftibuten—Dyspnoea—Cisplatin—urinary bladder cancer	0.00224	0.00229	CcSEcCtD
Ceftibuten—SLC15A1—renal system—urinary bladder cancer	0.00222	0.143	CbGeAlD
Ceftibuten—Anorexia—Etoposide—urinary bladder cancer	0.0022	0.00224	CcSEcCtD
Ceftibuten—Diarrhoea—Thiotepa—urinary bladder cancer	0.0022	0.00224	CcSEcCtD
Ceftibuten—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.00219	0.00223	CcSEcCtD
Ceftibuten—Decreased appetite—Cisplatin—urinary bladder cancer	0.00219	0.00223	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00217	0.00222	CcSEcCtD
Ceftibuten—Pancytopenia—Epirubicin—urinary bladder cancer	0.00216	0.0022	CcSEcCtD
Ceftibuten—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.00215	0.00219	CcSEcCtD
Ceftibuten—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00213	0.00218	CcSEcCtD
Ceftibuten—Renal failure—Methotrexate—urinary bladder cancer	0.00213	0.00217	CcSEcCtD
Ceftibuten—Neutropenia—Epirubicin—urinary bladder cancer	0.00213	0.00217	CcSEcCtD
Ceftibuten—Dysuria—Epirubicin—urinary bladder cancer	0.00213	0.00217	CcSEcCtD
Ceftibuten—Dizziness—Thiotepa—urinary bladder cancer	0.00212	0.00216	CcSEcCtD
Ceftibuten—Urticaria—Fluorouracil—urinary bladder cancer	0.00211	0.00215	CcSEcCtD
Ceftibuten—Body temperature increased—Fluorouracil—urinary bladder cancer	0.0021	0.00214	CcSEcCtD
Ceftibuten—Paraesthesia—Etoposide—urinary bladder cancer	0.00207	0.00211	CcSEcCtD
Ceftibuten—Haematuria—Methotrexate—urinary bladder cancer	0.00207	0.00211	CcSEcCtD
Ceftibuten—Dyspnoea—Etoposide—urinary bladder cancer	0.00206	0.0021	CcSEcCtD
Ceftibuten—Somnolence—Etoposide—urinary bladder cancer	0.00205	0.00209	CcSEcCtD
Ceftibuten—Vomiting—Thiotepa—urinary bladder cancer	0.00204	0.00208	CcSEcCtD
Ceftibuten—SLC15A2—prostate gland—urinary bladder cancer	0.00204	0.131	CbGeAlD
Ceftibuten—Rash—Thiotepa—urinary bladder cancer	0.00202	0.00206	CcSEcCtD
Ceftibuten—Dermatitis—Thiotepa—urinary bladder cancer	0.00202	0.00206	CcSEcCtD
Ceftibuten—Agranulocytosis—Methotrexate—urinary bladder cancer	0.00202	0.00206	CcSEcCtD
Ceftibuten—Headache—Thiotepa—urinary bladder cancer	0.00201	0.00205	CcSEcCtD
Ceftibuten—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.00201	0.00205	CcSEcCtD
Ceftibuten—Decreased appetite—Etoposide—urinary bladder cancer	0.002	0.00204	CcSEcCtD
Ceftibuten—Pancytopenia—Doxorubicin—urinary bladder cancer	0.002	0.00204	CcSEcCtD
Ceftibuten—Renal failure—Epirubicin—urinary bladder cancer	0.00199	0.00203	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00199	0.00203	CcSEcCtD
Ceftibuten—Body temperature increased—Cisplatin—urinary bladder cancer	0.00199	0.00203	CcSEcCtD
Ceftibuten—Fatigue—Etoposide—urinary bladder cancer	0.00199	0.00203	CcSEcCtD
Ceftibuten—Jaundice—Epirubicin—urinary bladder cancer	0.00198	0.00201	CcSEcCtD
Ceftibuten—Constipation—Etoposide—urinary bladder cancer	0.00197	0.00201	CcSEcCtD
Ceftibuten—Dysuria—Doxorubicin—urinary bladder cancer	0.00197	0.00201	CcSEcCtD
Ceftibuten—Neutropenia—Doxorubicin—urinary bladder cancer	0.00197	0.00201	CcSEcCtD
Ceftibuten—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00196	0.00199	CcSEcCtD
Ceftibuten—Haemoglobin—Methotrexate—urinary bladder cancer	0.00195	0.00199	CcSEcCtD
Ceftibuten—Haemorrhage—Methotrexate—urinary bladder cancer	0.00194	0.00198	CcSEcCtD
Ceftibuten—Asthenia—Gemcitabine—urinary bladder cancer	0.00194	0.00198	CcSEcCtD
Ceftibuten—Haematuria—Epirubicin—urinary bladder cancer	0.00193	0.00197	CcSEcCtD
Ceftibuten—Pruritus—Gemcitabine—urinary bladder cancer	0.00191	0.00195	CcSEcCtD
Ceftibuten—Nausea—Thiotepa—urinary bladder cancer	0.00191	0.00194	CcSEcCtD
Ceftibuten—Agranulocytosis—Epirubicin—urinary bladder cancer	0.00189	0.00193	CcSEcCtD
Ceftibuten—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00189	0.00192	CcSEcCtD
Ceftibuten—Pruritus—Fluorouracil—urinary bladder cancer	0.00188	0.00192	CcSEcCtD
Ceftibuten—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00186	0.0019	CcSEcCtD
Ceftibuten—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00185	0.00189	CcSEcCtD
Ceftibuten—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00185	0.00188	CcSEcCtD
Ceftibuten—Renal failure—Doxorubicin—urinary bladder cancer	0.00184	0.00188	CcSEcCtD
Ceftibuten—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00184	0.00187	CcSEcCtD
Ceftibuten—Urticaria—Etoposide—urinary bladder cancer	0.00183	0.00187	CcSEcCtD
Ceftibuten—Haemoglobin—Epirubicin—urinary bladder cancer	0.00183	0.00186	CcSEcCtD
Ceftibuten—Jaundice—Doxorubicin—urinary bladder cancer	0.00183	0.00186	CcSEcCtD
Ceftibuten—Abdominal pain—Etoposide—urinary bladder cancer	0.00182	0.00186	CcSEcCtD
Ceftibuten—Body temperature increased—Etoposide—urinary bladder cancer	0.00182	0.00186	CcSEcCtD
Ceftibuten—Haemorrhage—Epirubicin—urinary bladder cancer	0.00182	0.00186	CcSEcCtD
Ceftibuten—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00182	0.00185	CcSEcCtD
Ceftibuten—Asthenia—Cisplatin—urinary bladder cancer	0.00181	0.00184	CcSEcCtD
Ceftibuten—Haematuria—Doxorubicin—urinary bladder cancer	0.00179	0.00182	CcSEcCtD
Ceftibuten—Dizziness—Fluorouracil—urinary bladder cancer	0.00176	0.00179	CcSEcCtD
Ceftibuten—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.00175	0.00178	CcSEcCtD
Ceftibuten—Chills—Methotrexate—urinary bladder cancer	0.00174	0.00178	CcSEcCtD
Ceftibuten—Diarrhoea—Cisplatin—urinary bladder cancer	0.00172	0.00176	CcSEcCtD
Ceftibuten—SLC15A2—seminal vesicle—urinary bladder cancer	0.00172	0.111	CbGeAlD
Ceftibuten—Erythema multiforme—Epirubicin—urinary bladder cancer	0.00172	0.00175	CcSEcCtD
Ceftibuten—Vomiting—Gemcitabine—urinary bladder cancer	0.00172	0.00175	CcSEcCtD
Ceftibuten—Rash—Gemcitabine—urinary bladder cancer	0.0017	0.00174	CcSEcCtD
Ceftibuten—Dermatitis—Gemcitabine—urinary bladder cancer	0.0017	0.00173	CcSEcCtD
Ceftibuten—Hypersensitivity—Etoposide—urinary bladder cancer	0.0017	0.00173	CcSEcCtD
Ceftibuten—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00169	0.00173	CcSEcCtD
Ceftibuten—Headache—Gemcitabine—urinary bladder cancer	0.00169	0.00172	CcSEcCtD
Ceftibuten—Vomiting—Fluorouracil—urinary bladder cancer	0.00169	0.00172	CcSEcCtD
Ceftibuten—Haemorrhage—Doxorubicin—urinary bladder cancer	0.00168	0.00172	CcSEcCtD
Ceftibuten—Rash—Fluorouracil—urinary bladder cancer	0.00167	0.00171	CcSEcCtD
Ceftibuten—Dermatitis—Fluorouracil—urinary bladder cancer	0.00167	0.00171	CcSEcCtD
Ceftibuten—Headache—Fluorouracil—urinary bladder cancer	0.00166	0.0017	CcSEcCtD
Ceftibuten—Dysgeusia—Methotrexate—urinary bladder cancer	0.00166	0.00169	CcSEcCtD
Ceftibuten—Asthenia—Etoposide—urinary bladder cancer	0.00165	0.00169	CcSEcCtD
Ceftibuten—Chills—Epirubicin—urinary bladder cancer	0.00163	0.00166	CcSEcCtD
Ceftibuten—Pruritus—Etoposide—urinary bladder cancer	0.00163	0.00166	CcSEcCtD
Ceftibuten—SLC15A1—vagina—urinary bladder cancer	0.00161	0.104	CbGeAlD
Ceftibuten—Nausea—Gemcitabine—urinary bladder cancer	0.0016	0.00164	CcSEcCtD
Ceftibuten—Vomiting—Cisplatin—urinary bladder cancer	0.0016	0.00163	CcSEcCtD
Ceftibuten—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.00159	0.00162	CcSEcCtD
Ceftibuten—Rash—Cisplatin—urinary bladder cancer	0.00159	0.00162	CcSEcCtD
Ceftibuten—Dermatitis—Cisplatin—urinary bladder cancer	0.00159	0.00162	CcSEcCtD
Ceftibuten—Diarrhoea—Etoposide—urinary bladder cancer	0.00158	0.00161	CcSEcCtD
Ceftibuten—Nausea—Fluorouracil—urinary bladder cancer	0.00158	0.00161	CcSEcCtD
Ceftibuten—Flatulence—Epirubicin—urinary bladder cancer	0.00156	0.00159	CcSEcCtD
Ceftibuten—Dysgeusia—Epirubicin—urinary bladder cancer	0.00155	0.00158	CcSEcCtD
Ceftibuten—Dizziness—Etoposide—urinary bladder cancer	0.00152	0.00155	CcSEcCtD
Ceftibuten—Chills—Doxorubicin—urinary bladder cancer	0.00151	0.00154	CcSEcCtD
Ceftibuten—Nausea—Cisplatin—urinary bladder cancer	0.0015	0.00152	CcSEcCtD
Ceftibuten—Convulsion—Methotrexate—urinary bladder cancer	0.00147	0.0015	CcSEcCtD
Ceftibuten—Vomiting—Etoposide—urinary bladder cancer	0.00147	0.00149	CcSEcCtD
Ceftibuten—Agitation—Epirubicin—urinary bladder cancer	0.00146	0.00148	CcSEcCtD
Ceftibuten—Rash—Etoposide—urinary bladder cancer	0.00145	0.00148	CcSEcCtD
Ceftibuten—Dermatitis—Etoposide—urinary bladder cancer	0.00145	0.00148	CcSEcCtD
Ceftibuten—Headache—Etoposide—urinary bladder cancer	0.00144	0.00147	CcSEcCtD
Ceftibuten—Flatulence—Doxorubicin—urinary bladder cancer	0.00144	0.00147	CcSEcCtD
Ceftibuten—Dysgeusia—Doxorubicin—urinary bladder cancer	0.00144	0.00146	CcSEcCtD
Ceftibuten—SLC15A2—renal system—urinary bladder cancer	0.00139	0.0895	CbGeAlD
Ceftibuten—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00138	0.00141	CcSEcCtD
Ceftibuten—Convulsion—Epirubicin—urinary bladder cancer	0.00137	0.0014	CcSEcCtD
Ceftibuten—Nausea—Etoposide—urinary bladder cancer	0.00137	0.0014	CcSEcCtD
Ceftibuten—SLC15A2—urethra—urinary bladder cancer	0.00136	0.088	CbGeAlD
Ceftibuten—Agitation—Doxorubicin—urinary bladder cancer	0.00135	0.00137	CcSEcCtD
Ceftibuten—Dry mouth—Epirubicin—urinary bladder cancer	0.00132	0.00134	CcSEcCtD
Ceftibuten—Anorexia—Methotrexate—urinary bladder cancer	0.00132	0.00134	CcSEcCtD
Ceftibuten—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00129	0.00132	CcSEcCtD
Ceftibuten—Convulsion—Doxorubicin—urinary bladder cancer	0.00127	0.00129	CcSEcCtD
Ceftibuten—Insomnia—Methotrexate—urinary bladder cancer	0.00125	0.00127	CcSEcCtD
Ceftibuten—Paraesthesia—Methotrexate—urinary bladder cancer	0.00124	0.00126	CcSEcCtD
Ceftibuten—Anorexia—Epirubicin—urinary bladder cancer	0.00123	0.00126	CcSEcCtD
Ceftibuten—Dyspnoea—Methotrexate—urinary bladder cancer	0.00123	0.00126	CcSEcCtD
Ceftibuten—Somnolence—Methotrexate—urinary bladder cancer	0.00123	0.00125	CcSEcCtD
Ceftibuten—Dry mouth—Doxorubicin—urinary bladder cancer	0.00122	0.00124	CcSEcCtD
Ceftibuten—Dyspepsia—Methotrexate—urinary bladder cancer	0.00122	0.00124	CcSEcCtD
Ceftibuten—Decreased appetite—Methotrexate—urinary bladder cancer	0.0012	0.00122	CcSEcCtD
Ceftibuten—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.0012	0.00122	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00119	0.00122	CcSEcCtD
Ceftibuten—Fatigue—Methotrexate—urinary bladder cancer	0.00119	0.00121	CcSEcCtD
Ceftibuten—Insomnia—Epirubicin—urinary bladder cancer	0.00117	0.00119	CcSEcCtD
Ceftibuten—Paraesthesia—Epirubicin—urinary bladder cancer	0.00116	0.00118	CcSEcCtD
Ceftibuten—Dyspnoea—Epirubicin—urinary bladder cancer	0.00115	0.00117	CcSEcCtD
Ceftibuten—Somnolence—Epirubicin—urinary bladder cancer	0.00115	0.00117	CcSEcCtD
Ceftibuten—Anorexia—Doxorubicin—urinary bladder cancer	0.00114	0.00116	CcSEcCtD
Ceftibuten—Dyspepsia—Epirubicin—urinary bladder cancer	0.00114	0.00116	CcSEcCtD
Ceftibuten—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00113	0.00115	CcSEcCtD
Ceftibuten—Decreased appetite—Epirubicin—urinary bladder cancer	0.00112	0.00115	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00112	0.00114	CcSEcCtD
Ceftibuten—Fatigue—Epirubicin—urinary bladder cancer	0.00111	0.00114	CcSEcCtD
Ceftibuten—SLC15A2—female reproductive system—urinary bladder cancer	0.00111	0.0717	CbGeAlD
Ceftibuten—Constipation—Epirubicin—urinary bladder cancer	0.00111	0.00113	CcSEcCtD
Ceftibuten—Urticaria—Methotrexate—urinary bladder cancer	0.0011	0.00112	CcSEcCtD
Ceftibuten—Body temperature increased—Methotrexate—urinary bladder cancer	0.00109	0.00111	CcSEcCtD
Ceftibuten—Abdominal pain—Methotrexate—urinary bladder cancer	0.00109	0.00111	CcSEcCtD
Ceftibuten—Insomnia—Doxorubicin—urinary bladder cancer	0.00108	0.0011	CcSEcCtD
Ceftibuten—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00107	0.0011	CcSEcCtD
Ceftibuten—Dyspnoea—Doxorubicin—urinary bladder cancer	0.00107	0.00109	CcSEcCtD
Ceftibuten—Somnolence—Doxorubicin—urinary bladder cancer	0.00106	0.00108	CcSEcCtD
Ceftibuten—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00106	0.00108	CcSEcCtD
Ceftibuten—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00105	0.00107	CcSEcCtD
Ceftibuten—Decreased appetite—Doxorubicin—urinary bladder cancer	0.00104	0.00106	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00103	0.00105	CcSEcCtD
Ceftibuten—Fatigue—Doxorubicin—urinary bladder cancer	0.00103	0.00105	CcSEcCtD
Ceftibuten—Urticaria—Epirubicin—urinary bladder cancer	0.00103	0.00105	CcSEcCtD
Ceftibuten—Constipation—Doxorubicin—urinary bladder cancer	0.00102	0.00104	CcSEcCtD
Ceftibuten—Abdominal pain—Epirubicin—urinary bladder cancer	0.00102	0.00104	CcSEcCtD
Ceftibuten—Body temperature increased—Epirubicin—urinary bladder cancer	0.00102	0.00104	CcSEcCtD
Ceftibuten—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00102	0.00104	CcSEcCtD
Ceftibuten—SLC15A2—vagina—urinary bladder cancer	0.001	0.0649	CbGeAlD
Ceftibuten—Asthenia—Methotrexate—urinary bladder cancer	0.000991	0.00101	CcSEcCtD
Ceftibuten—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000978	0.000997	CcSEcCtD
Ceftibuten—Pruritus—Methotrexate—urinary bladder cancer	0.000977	0.000996	CcSEcCtD
Ceftibuten—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000952	0.000971	CcSEcCtD
Ceftibuten—Urticaria—Doxorubicin—urinary bladder cancer	0.00095	0.000969	CcSEcCtD
Ceftibuten—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000946	0.000964	CcSEcCtD
Ceftibuten—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000946	0.000964	CcSEcCtD
Ceftibuten—Diarrhoea—Methotrexate—urinary bladder cancer	0.000945	0.000964	CcSEcCtD
Ceftibuten—Asthenia—Epirubicin—urinary bladder cancer	0.000927	0.000946	CcSEcCtD
Ceftibuten—Pruritus—Epirubicin—urinary bladder cancer	0.000915	0.000932	CcSEcCtD
Ceftibuten—Dizziness—Methotrexate—urinary bladder cancer	0.000913	0.000931	CcSEcCtD
Ceftibuten—Diarrhoea—Epirubicin—urinary bladder cancer	0.000884	0.000902	CcSEcCtD
Ceftibuten—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000881	0.000898	CcSEcCtD
Ceftibuten—Vomiting—Methotrexate—urinary bladder cancer	0.000878	0.000895	CcSEcCtD
Ceftibuten—Rash—Methotrexate—urinary bladder cancer	0.000871	0.000888	CcSEcCtD
Ceftibuten—Dermatitis—Methotrexate—urinary bladder cancer	0.00087	0.000887	CcSEcCtD
Ceftibuten—Headache—Methotrexate—urinary bladder cancer	0.000865	0.000882	CcSEcCtD
Ceftibuten—Asthenia—Doxorubicin—urinary bladder cancer	0.000858	0.000875	CcSEcCtD
Ceftibuten—Dizziness—Epirubicin—urinary bladder cancer	0.000855	0.000872	CcSEcCtD
Ceftibuten—Pruritus—Doxorubicin—urinary bladder cancer	0.000846	0.000863	CcSEcCtD
Ceftibuten—Vomiting—Epirubicin—urinary bladder cancer	0.000822	0.000838	CcSEcCtD
Ceftibuten—Nausea—Methotrexate—urinary bladder cancer	0.00082	0.000837	CcSEcCtD
Ceftibuten—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000818	0.000834	CcSEcCtD
Ceftibuten—Rash—Epirubicin—urinary bladder cancer	0.000815	0.000831	CcSEcCtD
Ceftibuten—Dermatitis—Epirubicin—urinary bladder cancer	0.000814	0.00083	CcSEcCtD
Ceftibuten—Headache—Epirubicin—urinary bladder cancer	0.00081	0.000826	CcSEcCtD
Ceftibuten—Dizziness—Doxorubicin—urinary bladder cancer	0.000791	0.000806	CcSEcCtD
Ceftibuten—Nausea—Epirubicin—urinary bladder cancer	0.000768	0.000783	CcSEcCtD
Ceftibuten—Vomiting—Doxorubicin—urinary bladder cancer	0.00076	0.000775	CcSEcCtD
Ceftibuten—Rash—Doxorubicin—urinary bladder cancer	0.000754	0.000769	CcSEcCtD
Ceftibuten—Dermatitis—Doxorubicin—urinary bladder cancer	0.000753	0.000768	CcSEcCtD
Ceftibuten—Headache—Doxorubicin—urinary bladder cancer	0.000749	0.000764	CcSEcCtD
Ceftibuten—Nausea—Doxorubicin—urinary bladder cancer	0.00071	0.000724	CcSEcCtD
Ceftibuten—SLC15A2—lymph node—urinary bladder cancer	0.00065	0.042	CbGeAlD
